GFAP and Alzheimer disease: On the other hand, the results of the parallel test showed that serum SV2A combined with GFAP and p-tau217 increased the screening sensitivity for individuals at high risk of AD to 89.1% and 92.7%, respectively, and the sensitivity of the diagnosis with the above four biomarkers combined reached 100.0% (Table 6).